Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | AZD4573 |
Trade Name | |
Synonyms | AZD-4573|AZD 4573 |
Drug Descriptions |
AZD4573 is a selective inhibitor of Cdk9 that suppresses Mcl1 expression thus leads to apoptosis in tumor cells (Cancer Res 2018;78(13 Suppl):Abstract nr 310, PMID: 32175313, PMID: 31699827). |
DrugClasses | CDK9 Inhibitor 21 |
CAS Registry Number | 2057509-72-3 |
NCIT ID | C153377 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Acalabrutinib + AZD4573 | AZD4573 Acalabrutinib | 0 | 1 |
AZD4573 | AZD4573 | 0 | 2 |
AZD4573 + Fulvestrant + Palbociclib | AZD4573 Fulvestrant Palbociclib | 0 | 0 |
AZD4573 + Palbociclib | AZD4573 Palbociclib | 0 | 0 |
AZD4573 + Venetoclax | AZD4573 Venetoclax | 0 | 0 |